

5 March 2025

GE HealthCare launches new “Genesis” portfolio in global collaboration with Enlitic

Highlights

- GE HealthCare has launched its new “Genesis” portfolio of products, and in doing so, has revealed further details relating to its collaboration with Enlitic.
 - Enlitic is a foundational collaborator in GE HealthCare’s new Genesis portfolio of products designed to facilitate and accelerate the adoption of cloud technologies by healthcare providers, announced today by GE HealthCare at HIMSS.
 - Enlitic’s Insight Suite was announced by GE HealthCare as one of four key features of the new Genesis portfolio to provide large-scale, AI-enabled medical imaging migrations to support easier, more accessible storage and management of large volumes of medical images
 - In collaboration with GE HealthCare, Enlitic is working with Amazon Web Services (AWS) to deploy the solutions to the cloud
-

Enlitic, Inc. (ASX: ENL) (“the Company”) is pleased to provide further information relating to its previously announced collaboration with GE HealthCare, following the announcement by GE HealthCare today of the launch of its new Genesis portfolio, a new cloud-suite of enterprise imaging solutions designed to help improve patient care coordination, reduce operational costs, and maintain robust security standards.

At today’s launch of GE HealthCare’s new Genesis portfolio of products at the HIMSS Global Health Conference & Exhibition in Las Vegas, GE HealthCare shared insights into the functionality of its Genesis portfolio. Enlitic’s data standardisation and migration capability is included as a key feature of this new portfolio.

The Genesis portfolio will be deployed on the Amazon Web Services (AWS) cloud, and will include four key features:

1. **Edge:** acting as an on-ramp to Genesis solutions by managing data flows with a highly secure bi-directional pathway to the cloud.

2. **Storage:** a cloud-based Software as a Service (SaaS) that allows organisations to redirect time and resources from managing imaging data to focusing on higher value information technology projects and services.
3. **Vendor Neutral Archive (VNA):** a fully managed SaaS archive solution that unifies and intelligently manages patient data, images and enterprise content.
4. **AI-enabled medical imaging migration:** Through the collaboration with **Enlitic**, the Genesis portfolio will enable large-scale, AI-enabled medical imaging migrations by utilising standardised, high-quality imaging data essential for next-generation HealthCare solutions. This streamlines cloud transitions so healthcare providers worldwide can adopt modern infrastructures more efficiently.

Michael Sistenich, CEO of Enlitic, commented from the HIMSS Global Health Conference & Exhibition: “As this collaboration gathers momentum, we are fully engaged with GE HealthCare and AWS to bring this innovative solution to market. In collaboration with GE HealthCare, our Ensign Suite facilitates an on ramp to the cloud for customers of the new Genesis portfolio, standardising and migrating their data to the cloud and facilitating full use of the key features of this powerful technology.”

Specific details of the collaboration between GE HealthCare and the Company, including financial terms and conditions, are being finalised between the parties and will be disclosed by the Company to the market in due course in accordance with its continuous disclosure obligations.

GE HealthCare’s full Press Release can be read [here](#).

– ENDS –

This announcement was authorised for release by the Board of Enlitic, Inc.

Enquiries

Enlitic Investor Relations

Australia:
invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.